Michael B. Atkins

93.9k total citations · 18 hit papers
577 papers, 40.7k citations indexed

About

Michael B. Atkins is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Michael B. Atkins has authored 577 papers receiving a total of 40.7k indexed citations (citations by other indexed papers that have themselves been cited), including 368 papers in Oncology, 280 papers in Pulmonary and Respiratory Medicine and 214 papers in Molecular Biology. Recurrent topics in Michael B. Atkins's work include Renal cell carcinoma treatment (239 papers), Cancer Immunotherapy and Biomarkers (224 papers) and CAR-T cell therapy research (129 papers). Michael B. Atkins is often cited by papers focused on Renal cell carcinoma treatment (239 papers), Cancer Immunotherapy and Biomarkers (224 papers) and CAR-T cell therapy research (129 papers). Michael B. Atkins collaborates with scholars based in United States, United Kingdom and France. Michael B. Atkins's co-authors include David F. McDermott, John M. Kirkwood, Arthur J. Sober, Geoffrey T. Gibney, Brian I. Rini, Janice P. Dutcher, James W. Mier, John F. Thompson, Charles M. Balch and Kelly M. McMasters and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Michael B. Atkins

565 papers receiving 39.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Final Version of 2009 AJCC Melanoma Staging and Classification

2009 3.3k citations Charles M. Balch, Jeffrey E. Gershenwald et al. Journal of Clinical Oncology profile →
Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma

2001 2.0k citations Charles M. Balch, Antônio C. Buzaid et al. Journal of Clinical Oncology profile →
Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System

2001 1.8k citations Charles M. Balch, Jeffrey E. Gershenwald et al. Journal of Clinical Oncology profile →
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

2009 1.5k citations David F. McDermott, Michael B. Atkins et al. Journal of Clinical Oncology profile →
High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

1999 1.5k citations Michael B. Atkins, Janice P. Dutcher et al. Journal of Clinical Oncology profile →
Predictive biomarkers for checkpoint inhibitor-based immunotherapy

2016 1.3k citations Michael B. Atkins et al. profile →
Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

2004 742 citations Michael B. Atkins, Janice P. Dutcher et al. Journal of Clinical Oncology profile →
Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.

1997 684 citations Matthew L. Sherman, Michael B. Atkins et al. profile →
Arginase-Producing Myeloid Suppressor Cells in Renal Cell Carcinoma Patients: A Mechanism of Tumor Evasion

2005 671 citations Arnold H. Zea, Paulo C. Rodrı́guez et al. Cancer Research profile →
Management of Cutaneous Melanoma

2004 654 citations Michael B. Atkins, Arthur J. Sober et al. profile →
Arginase I–Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes

2009 634 citations Paulo C. Rodrı́guez, Marc S. Ernstoff et al. Cancer Research profile →
Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

2004 598 citations John M. Kirkwood, Jeffrey A. Sosman et al. Journal of Clinical Oncology profile →
Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

2008 534 citations Vernon K. Sondak, Michael B. Atkins et al. Journal of Clinical Oncology profile →
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

2020 498 citations Elizabeth R. Plimack, Ray McDermott et al. profile →
Toxicities of Immunotherapy for the Practitioner

2015 465 citations Michael B. Atkins et al. Journal of Clinical Oncology profile →
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

2019 409 citations F. Stephen Hodi, David F. McDermott et al. profile →
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial

2018 274 citations Michael B. Atkins, Elizabeth R. Plimack et al. profile →
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma

2021 183 citations David F. McDermott, Rodolfo F. Perini et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Michael B. Atkins

Since Specialization

Citations

This map shows the geographic impact of Michael B. Atkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael B. Atkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael B. Atkins more than expected).

Fields of papers citing papers by Michael B. Atkins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael B. Atkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael B. Atkins. The network helps show where Michael B. Atkins may publish in the future.

Co-authorship network of co-authors of Michael B. Atkins

This figure shows the co-authorship network connecting the top 25 collaborators of Michael B. Atkins. A scholar is included among the top collaborators of Michael B. Atkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael B. Atkins. Michael B. Atkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1881O Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase II LITESPARK-013 study 2023 ·Annals of Oncology ·(unknown), James Brugarolas, Pooja Ghatalia, S. George, John B.A.G. Haanen, (unknown), Rahul Ravilla, Astrid A.M. van der Veldt, (unknown), И. А. Покатаев, (unknown), Mark Tuthill, Daniel A. Vaena, Flora Zagouri, Jane Wu, (unknown), Rodolfo F. Perini, (unknown), Michael B. Atkins	4
2	Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B) 2023 ·Journal for ImmunoTherapy of Cancer ·Michael B. Atkins, Opeyemi A. Jegede, Naomi B. Haas, David F. McDermott, Mehmet Asım Bilen, Mark N. Stein, Jeffrey A. Sosman, Robert Alter, Elizabeth R. Plimack, Moshe Chaim Ornstein, Michael E. Hurwitz, David Peace, Sabina Signoretti, Thomas Denize, Alessia Cimadamore, Catherine J. Wu, David A. Braun, David J. Einstein, Paul J. Catalano, Hans J. Hammers	19
3	Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma 2022 ·Clinical Cancer Research ·Thomas Denize, Yue Hou, Jean‐Christophe Pignon, Emily Walton, (unknown), Gordon J. Freeman, David A. Braun, Catherine J. Wu, Saurabh Gupta, Robert J. Motzer, Michael B. Atkins, David F. McDermott, Toni K. Choueiri, Sachet A. Shukla, Sabina Signoretti	13
4	Automated Identification of Patients With Immune-Related Adverse Events From Clinical Notes Using Word Embedding and Machine Learning 2021 ·JCO Clinical Cancer Informatics ·Samir Gupta, Anas Belouali, Neil J. Shah, Michael B. Atkins, Subha Madhavan	16
5	Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma 2020 ·Clinical Cancer Research ·Jean-François Martini, Elizabeth R. Plimack, Toni K. Choueiri, David F. McDermott, Igor Puzanov, Mayer Fishman, Daniel C. Cho, Ulka N. Vaishampayan, (unknown), Kathrine C. Fernandez, Jamal Tarazi, Saby George, Michael B. Atkins	16
6	Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma 2019 ·Clinical Cancer Research ·Wenxin Xu, Mäneka Puligandla, Judith Manola, Andrea J. Bullock, Daniel Tamasauskas, David F. McDermott, Michael B. Atkins, Naomi B. Haas, Keith T. Flaherty, Robert G. Uzzo, Janice P. Dutcher, Robert S. DiPaola, Rupal S. Bhatt	11
7	Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study 2018 ·Clinical Cancer Research ·Michael B. Atkins, F. Stephen Hodi, John A. Thompson, Ray McDermott, Wen‐Jen Hwu, Donald P. Lawrence, Nancy A. Dawson, (unknown), Shailender Bhatia, (unknown), Lokesh Jain, Seth Robey, Xinxin Shu, Blanca Homet Moreno, Rodolfo F. Perini, Toni K. Choueiri, Antoni Ribas	48
8	Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697) 2017 ·Clinical Cancer Research ·Lisa H. Butterfield, Fengmin Zhao, Charles Lee, Ahmad A. Tarhini, Kim Margolin, Richard L. White, Michael B. Atkins, Gary I. Cohen, Theresa L. Whiteside, John M. Kirkwood, David H. Lawson	35
9	Indoor Tanning Dependence in Young Adult Women 2017 ·Cancer Epidemiology Biomarkers & Prevention ·Darren Mays, Michael B. Atkins, Jaeil Ahn, Kenneth P. Tercyak	11
10	FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma 2016 ·Clinical Cancer Research ·Amy K. Erbe, Wei Wang, Jacob L. Goldberg, (unknown), KyungMann Kim, Lakeesha Carmichael, (unknown), Eneida A. Mendonça, (unknown), Jacquelyn A. Hank, Su–Chun Cheng, Sabina Signoretti, Michael B. Atkins, (unknown), James W. Mier, David J. Panka, David F. McDermott, Paul M. Sondel	12
11	The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma 2016 ·Clinical Cancer Research ·Martin H. Voss, Rupal S. Bhatt, Elizabeth R. Plimack, Brian I. Rini, Robert Alter, J. Thaddeus Beck, Dawn Wilson, Xiaosha Zhang, (unknown), Chad Glasser, Kenneth M. Attie, Matthew L. Sherman, Shuchi S. Pandya, Michael B. Atkins	21
12	Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805 2015 ·Clinical Cancer Research ·Naomi B. Haas, Judith Manola, Bonnie Ky, Keith T. Flaherty, Robert G. Uzzo, Christopher J. Kane, Michael A.S. Jewett, Lori Wood, Christopher G. Wood, Michael B. Atkins, Janice Dutcher, George Wilding, Robert S. DiPaola	46
13	Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer 2015 ·Clinical Cancer Research ·(unknown), Xiaoen Wang, Andrea J. Bullock, Marcella Callea, (unknown), Jiaxi Song, Kelli Moreno, Barbara Visentin, Douglas H. Deutschman, David C. Alsop, Michael B. Atkins, James W. Mier, Sabina Signoretti, Manoj Bhasin, Roger A. Sabbadini, Rupal S. Bhatt	67
14	Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma 2015 ·Cancer Immunology Research ·Marcella Callea, Laurence Albigès, Mamta Gupta, Su–Chun Cheng, Elizabeth M. Genega, André P. Fay, Jiaxi Song, Ingrid Carvo, Rupal S. Bhatt, Michael B. Atkins, F. Stephen Hodi, Toni K. Choueiri, David F. McDermott, Gordon J. Freeman, Sabina Signoretti	266
15	Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group 2011 ·Clinical Cancer Research ·Judith Manola, Patrick Royston, Paul Elson, (unknown), Madhu Mazumdar, Sylvie Négrier, Bernard Escudier, Tim Eisen, Janice P. Dutcher, Michael B. Atkins, Daniel Yick Chin Heng, Toni K. Choueiri, Robert J. Motzer, Ronald M. Bukowski	148
16	Renal Cancer Resistance to Antiangiogenic Therapy Is Delayed by Restoration of Angiostatic Signaling 2010 ·Molecular Cancer Therapeutics ·Rupal S. Bhatt, Xiaoen Wang, Liang Zhang, Michael P. Collins, Sabina Signoretti, David C. Alsop, S. Nahum Goldberg, Michael B. Atkins, James W. Mier	48
17	The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma 2010 ·Clinical Cancer Research ·Daniel C. Cho, (unknown), David J. Panka, Michael P. Collins, Musie Ghebremichael, Michael B. Atkins, Sabina Signoretti, James W. Mier	154
18	Arginase I–Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes breakdown → 2009 ·Cancer Research ·Paulo C. Rodrı́guez, Marc S. Ernstoff, Claudia Hernandez, Michael B. Atkins, Jovanny Zabaleta, Rosa A. Sierra, Augusto C. Ochoa	634
19	Final Version of 2009 AJCC Melanoma Staging and Classification breakdown → 2009 ·Journal of Clinical Oncology ·Charles M. Balch, Jeffrey E. Gershenwald, Seng-Jaw Soong, John F. Thompson, Michael B. Atkins, David R. Byrd, Antônio C. Buzaid, Alistair J. Cochran, Daniel G. Coit, Shouluan Ding, Alexander M.M. Eggermont, Keith T. Flaherty, Phyllis A. Gimotty, John M. Kirkwood, Kelly M. McMasters, Martín C. Mihm, Donald L. Morton, Merrick I. Ross, Arthur J. Sober, Vernon K. Sondak	3342
20	Arginase-Producing Myeloid Suppressor Cells in Renal Cell Carcinoma Patients: A Mechanism of Tumor Evasion breakdown → 2005 ·Cancer Research ·Arnold H. Zea, Paulo C. Rodrı́guez, Michael B. Atkins, Claudia Hernandez, Sabina Signoretti, Jovanny Zabaleta, David F. McDermott, David Quiceno, Amanda Youmans, Anne O’Neill, James W. Mier, Augusto C. Ochoa	671

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact